Incyte Corporation (INCY)
USD 58.34
(-3.71%)
USD 58.34
(-3.71%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.19 Billion USD | 7.51% |
| 2022 | 2.59 Billion USD | 16.17% |
| 2021 | 2.23 Billion USD | -19.49% |
| 2020 | 2.77 Billion USD | 71.04% |
| 2019 | 1.62 Billion USD | -0.58% |
| 2018 | 1.63 Billion USD | -3.57% |
| 2017 | 1.69 Billion USD | 91.25% |
| 2016 | 885.11 Million USD | 30.91% |
| 2015 | 676.12 Million USD | 31.72% |
| 2014 | 513.29 Million USD | 38.57% |
| 2013 | 370.41 Million USD | 25.25% |
| 2012 | 295.75 Million USD | 24.46% |
| 2011 | 237.63 Million USD | 52.5% |
| 2010 | 155.82 Million USD | 4.56% |
| 2009 | 149.03 Million USD | -8.69% |
| 2008 | 163.2 Million USD | 36.32% |
| 2007 | 119.72 Million USD | 14.56% |
| 2006 | 104.5 Million USD | -3.8% |
| 2005 | 108.63 Million USD | -33.36% |
| 2004 | 162.99 Million USD | 0.35% |
| 2003 | 162.43 Million USD | -18.59% |
| 2002 | 199.52 Million USD | -29.74% |
| 2001 | 283.96 Million USD | -2.62% |
| 2000 | 291.59 Million USD | 39.72% |
| 1999 | 208.7 Million USD | 48.65% |
| 1998 | 140.4 Million USD | 53.61% |
| 1997 | 91.4 Million USD | 68.63% |
| 1996 | 54.2 Million USD | 110.08% |
| 1995 | 25.8 Million USD | 95.45% |
| 1994 | 13.2 Million USD | 725.0% |
| 1993 | 1.6 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 1.42 Billion USD | 96.01% |
| 2024 Q3 | 882.37 Million USD | -36.57% |
| 2024 Q1 | 728.53 Million USD | -1.72% |
| 2023 Q1 | 720.88 Million USD | -6.75% |
| 2023 FY | 2.79 Billion USD | 7.51% |
| 2023 Q4 | 741.29 Million USD | 14.99% |
| 2023 Q2 | 684.1 Million USD | -5.1% |
| 2023 Q3 | 644.65 Million USD | -5.77% |
| 2022 FY | 2.59 Billion USD | 16.17% |
| 2022 Q1 | 567.69 Million USD | -19.65% |
| 2022 Q2 | 603.01 Million USD | 6.22% |
| 2022 Q3 | 652.27 Million USD | 8.17% |
| 2022 Q4 | 773.09 Million USD | 18.52% |
| 2021 FY | 2.23 Billion USD | -19.49% |
| 2021 Q4 | 706.57 Million USD | 32.12% |
| 2021 Q2 | 522.25 Million USD | 10.84% |
| 2021 Q3 | 534.79 Million USD | 2.4% |
| 2021 Q1 | 471.17 Million USD | -19.51% |
| 2020 Q4 | 585.36 Million USD | 2.0% |
| 2020 FY | 2.77 Billion USD | 71.04% |
| 2020 Q1 | 1.19 Billion USD | 166.91% |
| 2020 Q2 | 417.85 Million USD | -65.14% |
| 2020 Q3 | 573.89 Million USD | 37.34% |
| 2019 Q1 | 394.52 Million USD | -4.38% |
| 2019 Q4 | 449.04 Million USD | 16.96% |
| 2019 FY | 1.62 Billion USD | -0.58% |
| 2019 Q3 | 383.94 Million USD | -2.87% |
| 2019 Q2 | 395.3 Million USD | 0.2% |
| 2018 Q4 | 412.59 Million USD | 6.05% |
| 2018 FY | 1.63 Billion USD | -3.57% |
| 2018 Q3 | 389.04 Million USD | -4.2% |
| 2018 Q1 | 424.6 Million USD | -22.06% |
| 2018 Q2 | 406.11 Million USD | -4.35% |
| 2017 FY | 1.69 Billion USD | 91.25% |
| 2017 Q1 | 495.2 Million USD | 92.19% |
| 2017 Q2 | 291.91 Million USD | -41.05% |
| 2017 Q3 | 360.88 Million USD | 23.63% |
| 2017 Q4 | 544.76 Million USD | 50.95% |
| 2016 Q3 | 218.96 Million USD | 17.05% |
| 2016 Q2 | 187.06 Million USD | -15.52% |
| 2016 FY | 885.11 Million USD | 30.91% |
| 2016 Q4 | 257.67 Million USD | 17.68% |
| 2016 Q1 | 221.42 Million USD | 30.94% |
| 2015 Q4 | 169.09 Million USD | -5.89% |
| 2015 Q3 | 179.67 Million USD | 9.47% |
| 2015 Q1 | 163.23 Million USD | 10.92% |
| 2015 FY | 676.12 Million USD | 31.72% |
| 2015 Q2 | 164.12 Million USD | 0.54% |
| 2014 FY | 513.29 Million USD | 38.57% |
| 2014 Q4 | 147.16 Million USD | 14.99% |
| 2014 Q3 | 127.98 Million USD | 1.91% |
| 2014 Q2 | 125.58 Million USD | 11.57% |
| 2014 Q1 | 112.55 Million USD | -0.43% |
| 2013 FY | 370.41 Million USD | 25.25% |
| 2013 Q2 | 84.19 Million USD | 12.23% |
| 2013 Q1 | 75.02 Million USD | -10.14% |
| 2013 Q4 | 113.04 Million USD | 15.18% |
| 2013 Q3 | 98.15 Million USD | 16.57% |
| 2012 FY | 295.75 Million USD | 24.46% |
| 2012 Q2 | 71.3 Million USD | 1.35% |
| 2012 Q1 | 70.35 Million USD | -3.66% |
| 2012 Q4 | 83.49 Million USD | 18.26% |
| 2012 Q3 | 70.59 Million USD | -0.99% |
| 2011 Q3 | 58.88 Million USD | 1.66% |
| 2011 Q1 | 47.79 Million USD | 9.73% |
| 2011 Q4 | 73.02 Million USD | 24.02% |
| 2011 FY | 237.63 Million USD | 52.5% |
| 2011 Q2 | 57.92 Million USD | 21.19% |
| 2010 Q4 | 43.55 Million USD | 11.9% |
| 2010 Q2 | 36.22 Million USD | -2.41% |
| 2010 Q1 | 37.11 Million USD | -22.81% |
| 2010 FY | 155.82 Million USD | 4.56% |
| 2010 Q3 | 38.92 Million USD | 7.47% |
| 2009 Q2 | 33.52 Million USD | -3.98% |
| 2009 Q4 | 48.08 Million USD | 47.95% |
| 2009 FY | 149.03 Million USD | -8.69% |
| 2009 Q1 | 34.91 Million USD | -18.25% |
| 2009 Q3 | 32.5 Million USD | -3.06% |
| 2008 FY | 163.2 Million USD | 36.32% |
| 2008 Q1 | 37.3 Million USD | 1.78% |
| 2008 Q2 | 41.31 Million USD | 10.74% |
| 2008 Q3 | 40.95 Million USD | -0.88% |
| 2008 Q4 | 42.71 Million USD | 4.29% |
| 2007 Q1 | 27.59 Million USD | -7.14% |
| 2007 Q4 | 36.65 Million USD | 28.03% |
| 2007 Q3 | 28.63 Million USD | 6.69% |
| 2007 Q2 | 26.83 Million USD | -2.76% |
| 2007 FY | 119.72 Million USD | 14.56% |
| 2006 Q2 | 26.03 Million USD | -9.07% |
| 2006 Q3 | 23.01 Million USD | -11.61% |
| 2006 FY | 104.5 Million USD | -3.8% |
| 2006 Q4 | 29.72 Million USD | 29.15% |
| 2006 Q1 | 28.63 Million USD | 3.66% |
| 2005 Q4 | 27.62 Million USD | -9.03% |
| 2005 FY | 108.63 Million USD | -33.36% |
| 2005 Q2 | 29.73 Million USD | 42.22% |
| 2005 Q1 | 20.9 Million USD | -36.72% |
| 2005 Q3 | 30.36 Million USD | 2.12% |
| 2004 Q2 | 66.1 Million USD | 64.78% |
| 2004 Q1 | 40.11 Million USD | -17.7% |
| 2004 FY | 162.99 Million USD | 0.35% |
| 2004 Q3 | 23.73 Million USD | -64.1% |
| 2004 Q4 | 33.04 Million USD | 39.22% |
| 2003 Q1 | 38.66 Million USD | -3.14% |
| 2003 FY | 162.43 Million USD | -18.59% |
| 2003 Q4 | 48.74 Million USD | 31.15% |
| 2003 Q3 | 37.16 Million USD | -1.05% |
| 2003 Q2 | 37.56 Million USD | -2.85% |
| 2002 Q3 | 59.85 Million USD | 15.47% |
| 2002 FY | 199.52 Million USD | -29.74% |
| 2002 Q4 | 39.91 Million USD | -33.31% |
| 2002 Q2 | 51.83 Million USD | 8.19% |
| 2002 Q1 | 47.91 Million USD | -30.71% |
| 2001 Q1 | 72.52 Million USD | -10.63% |
| 2001 Q2 | 73.74 Million USD | 1.69% |
| 2001 Q3 | 68.54 Million USD | -7.05% |
| 2001 Q4 | 69.14 Million USD | 0.88% |
| 2001 FY | 283.96 Million USD | -2.62% |
| 2000 Q1 | 64.26 Million USD | 7.29% |
| 2000 Q3 | 77.36 Million USD | 12.41% |
| 2000 Q4 | 81.14 Million USD | 4.89% |
| 2000 FY | 291.59 Million USD | 39.72% |
| 2000 Q2 | 68.82 Million USD | 7.08% |
| 1999 Q4 | 59.9 Million USD | 15.64% |
| 1999 Q3 | 51.8 Million USD | -0.38% |
| 1999 Q2 | 52 Million USD | 15.56% |
| 1999 FY | 208.7 Million USD | 48.65% |
| 1999 Q1 | 45 Million USD | 8.17% |
| 1998 Q2 | 32.8 Million USD | 9.33% |
| 1998 Q4 | 41.6 Million USD | 15.56% |
| 1998 Q3 | 36 Million USD | 9.76% |
| 1998 Q1 | 30 Million USD | 13.64% |
| 1998 FY | 140.4 Million USD | 53.61% |
| 1997 FY | 91.4 Million USD | 68.63% |
| 1997 Q1 | 19.5 Million USD | 17.47% |
| 1997 Q2 | 22.1 Million USD | 13.33% |
| 1997 Q3 | 23.5 Million USD | 6.33% |
| 1997 Q4 | 26.4 Million USD | 12.34% |
| 1996 Q2 | 11.1 Million USD | 18.09% |
| 1996 Q3 | 15.6 Million USD | 40.54% |
| 1996 Q4 | 16.6 Million USD | 6.41% |
| 1996 FY | 54.2 Million USD | 110.08% |
| 1996 Q1 | 9.4 Million USD | 13.25% |
| 1995 Q1 | 4.1 Million USD | -12.77% |
| 1995 Q4 | 8.3 Million USD | 25.76% |
| 1995 Q3 | 6.6 Million USD | 15.79% |
| 1995 Q2 | 5.7 Million USD | 39.02% |
| 1995 FY | 25.8 Million USD | 95.45% |
| 1994 Q3 | 3.4 Million USD | 209.09% |
| 1994 Q2 | 1.1 Million USD | -52.17% |
| 1994 FY | 13.2 Million USD | 725.0% |
| 1994 Q1 | 2.3 Million USD | 666.67% |
| 1994 Q4 | 4.7 Million USD | 38.24% |
| 1993 FY | 1.6 Million USD | 0.0% |
| 1993 Q3 | 400 Thousand USD | 0.0% |
| 1993 Q4 | 300 Thousand USD | -25.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| AbCellera Biologics Inc. | 275.23 Million USD | -332.542% |
| Alkermes plc | 996.24 Million USD | -19.498% |
| Agenus Inc. | 78.18 Million USD | -1422.703% |
| Aptorum Group Limited | 10.56 Thousand USD | -11267125.062% |
| Ardelyx, Inc. | 169.93 Million USD | -600.551% |
| Dyadic International, Inc. | 9.15 Million USD | -12907.042% |
| Eton Pharmaceuticals, Inc. | 22.25 Million USD | -5249.818% |
| Lantern Pharma Inc. | 17.87 Million USD | -6559.154% |
| Inhibikase Therapeutics, Inc. | 6.73 Million USD | -17584.268% |
| Novavax, Inc. | 779.12 Million USD | -52.799% |
| Janux Therapeutics, Inc. | 81.06 Million USD | -1368.623% |
| Pyxis Oncology, Inc. | 82.19 Million USD | -1348.361% |
| TransCode Therapeutics, Inc. | 19.41 Million USD | -6030.721% |
| Ocuphire Pharma, Inc. | 29.6 Million USD | -3921.127% |
| Outlook Therapeutics, Inc. | 53.12 Million USD | -2140.873% |
| Madrigal Pharmaceuticals, Inc. | 380.49 Million USD | -212.88% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -4797.824% |
| SELLAS Life Sciences Group, Inc. | 37.86 Million USD | -3043.719% |
| Syros Pharmaceuticals, Inc. | 30.77 Million USD | -3768.886% |
| Barinthus Biotherapeutics plc | 84.71 Million USD | -1305.278% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | -6719.585% |
| Xeris Biopharma Holdings, Inc. | 168.43 Million USD | -606.794% |
| Clearside Biomedical, Inc. | 32.71 Million USD | -3538.988% |
| C4 Therapeutics, Inc. | 159.78 Million USD | -645.051% |
| Alnylam Pharmaceuticals, Inc. | 1.8 Billion USD | 33.864% |
| AlloVir, Inc. | 180.93 Million USD | -557.976% |
| Arrowhead Pharmaceuticals, Inc. | 445.73 Million USD | -167.085% |
| VYNE Therapeutics Inc. | 29.68 Million USD | -3910.831% |
| Bicycle Therapeutics plc | 216.92 Million USD | -448.812% |
| BioXcel Therapeutics, Inc. | 171.9 Million USD | -592.543% |
| ChromaDex Corporation | 56.37 Million USD | -2011.593% |
| Chimerix, Inc. | 93.38 Million USD | -1174.77% |
| Corbus Pharmaceuticals Holdings, Inc. | 13.9 Million USD | -8458.776% |
| Caribou Biosciences, Inc. | 150.53 Million USD | -690.837% |
| CRISPR Therapeutics AG | 463.49 Million USD | -156.852% |
| Precision BioSciences, Inc. | 92.46 Million USD | -1187.537% |
| Fate Therapeutics, Inc. | 254.04 Million USD | -368.618% |
| Fortress Biotech, Inc. | 200.19 Million USD | -494.668% |
| Fortress Biotech, Inc. | 200.19 Million USD | -494.668% |
| HOOKIPA Pharma Inc. | 32.74 Million USD | -3535.543% |
| ImmuCell Corporation | 9.61 Million USD | -12278.602% |
| IDEAYA Biosciences, Inc. | 157.81 Million USD | -654.366% |
| Immix Biopharma, Inc. | 16.14 Million USD | -7275.545% |
| Innoviva, Inc. | 132.15 Million USD | -800.839% |
| IO Biotech, Inc. | 91.44 Million USD | -1201.898% |
| Jaguar Health, Inc. | 42.01 Million USD | -2733.5% |
| Keros Therapeutics, Inc. | 169.27 Million USD | -603.282% |
| Ligand Pharmaceuticals Incorporated | 84.32 Million USD | -1311.827% |
| ContextLogic Inc. | 387 Million USD | -207.621% |
| MiMedx Group, Inc. | 229.72 Million USD | -418.222% |
| MEI Pharma, Inc. | 34.78 Million USD | -3322.438% |
| NextCure, Inc. | 67.63 Million USD | -1660.124% |
| Onconetix, Inc. | 34.9 Million USD | -3310.434% |
| Oncternal Therapeutics, Inc. | 12.74 Million USD | -9240.146% |
| Opthea Limited | 191.96 Million USD | -520.155% |
| Psyence Biomedical Ltd. | 2.75 Million USD | -43165.79% |
| Vaxcyte, Inc. | 468.04 Million USD | -154.357% |
| PDS Biotechnology Corporation | 43.04 Million USD | -2665.684% |
| Precigen, Inc. | 84.18 Million USD | -1314.209% |
| Pharming Group N.V. | 225.49 Million USD | -427.957% |
| Phathom Pharmaceuticals, Inc. | 167.82 Million USD | -609.358% |
| Pieris Pharmaceuticals, Inc. | 72.56 Million USD | -1540.569% |
| PureTech Health plc | 144.59 Million USD | -723.319% |
| Rigel Pharmaceuticals, Inc. | 130.26 Million USD | -813.916% |
| Avidity Biosciences, Inc. | 245.15 Million USD | -385.603% |
| Reviva Pharmaceuticals Holdings, Inc. | 24.3 Million USD | -4797.824% |
| Sangamo Therapeutics, Inc. | 228.68 Million USD | -420.594% |
| Sol-Gel Technologies Ltd. | 30.85 Million USD | -3757.853% |
| Acelyrin, Inc. | 422.06 Million USD | -182.065% |
| Salarius Pharmaceuticals, Inc. | 12.89 Thousand USD | -9232837.801% |
| Summit Therapeutics Inc. | 87.68 Million USD | -1257.68% |
| Sensei Biotherapeutics, Inc. | 37.06 Million USD | -3111.998% |
| Senti Biosciences, Inc. | 94.7 Million USD | -1157.056% |
| Stoke Therapeutics, Inc. | 123.55 Million USD | -863.55% |
| Elevation Oncology, Inc. | 45.44 Million USD | -2519.639% |
| Alaunos Therapeutics, Inc. | 29.46 Million USD | -3939.822% |
| Telomir Pharmaceuticals, Inc. Common Stock | 3.94 Million USD | -30099.911% |
| Entrada Therapeutics, Inc. | 132.17 Million USD | -800.696% |
| VistaGen Therapeutics, Inc. | 34.08 Million USD | -3392.724% |
| Kintara Therapeutics, Inc. | 8.45 Million USD | -13987.031% |
| Wave Life Sciences Ltd. | 181.3 Million USD | -556.64% |
| Seer, Inc. | 110.49 Million USD | -977.469% |
| Verrica Pharmaceuticals Inc. | 70.59 Million USD | -1586.397% |
| Aadi Bioscience, Inc. | 93.47 Million USD | -1173.556% |
| ESSA Pharma Inc. | 32.13 Million USD | -3604.771% |
| GlycoMimetics, Inc. | 39.28 Million USD | -2930.383% |
| GT Biopharma, Inc. | 13.57 Million USD | -8669.115% |
| Inhibrx Biosciences, Inc. | 219.83 Million USD | -441.553% |
| Akebia Therapeutics, Inc. | 201.11 Million USD | -491.947% |
| Catalyst Pharmaceuticals, Inc. | 259.42 Million USD | -358.898% |
| Longboard Pharmaceuticals, Inc. | 56.75 Million USD | -1997.456% |
| Orchestra BioMed Holdings, Inc. | 54.08 Million USD | -2101.359% |
| Alzamend Neuro, Inc. | 9.93 Million USD | -11879.649% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | -194.996% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -6189.265% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -2248.441% |
| Rocket Pharmaceuticals, Inc. | 259.65 Million USD | -358.484% |
| Aptose Biosciences Inc. | 52.35 Million USD | -2173.846% |
| ZyVersa Therapeutics, Inc. | 14.41 Million USD | -8161.375% |
| Soligenix, Inc. | 7.79 Million USD | -15172.055% |
| Century Therapeutics, Inc. | 56.07 Million USD | -2023.192% |
| Kura Oncology, Inc. | 165.8 Million USD | -618.013% |
| TScan Therapeutics, Inc. | 114.5 Million USD | -939.67% |
| Intensity Therapeutics, Inc. | 8.31 Million USD | -14210.554% |
| Ocean Biomedical, Inc. | 2.48 Million USD | -47872.126% |
| CytomX Therapeutics, Inc. | 107.69 Million USD | -1005.401% |
| Autolus Therapeutics plc | 196.72 Million USD | -505.154% |
| Mineralys Therapeutics, Inc. | 84.65 Million USD | -1306.257% |
| EyePoint Pharmaceuticals, Inc. | 116.45 Million USD | -922.297% |
| Eterna Therapeutics Inc. | 19.38 Million USD | -6041.954% |
| Adaptive Biotechnologies Corporation | 321.75 Million USD | -269.997% |
| GRI Bio, Inc. | 11.33 Million USD | -10407.458% |
| Xenetic Biosciences, Inc. | 7.05 Million USD | -16772.81% |
| Tenaya Therapeutics, Inc. | 131.19 Million USD | -807.438% |
| IGM Biosciences, Inc. | 265.59 Million USD | -348.244% |
| INmune Bio, Inc. | 29.89 Million USD | -3882.121% |
| Heron Therapeutics, Inc. | 172.55 Million USD | -589.926% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -2853.033% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -7350.204% |
| Entero Therapeutics, Inc. | 15.74 Million USD | -7462.754% |
| Milestone Pharmaceuticals Inc. | 62.09 Million USD | -1817.123% |
| X4 Pharmaceuticals, Inc. | 107.52 Million USD | -1007.211% |
| Atara Biotherapeutics, Inc. | 275.69 Million USD | -331.819% |
| Coherus BioSciences, Inc. | 301.45 Million USD | -294.922% |
| Verastem, Inc. | 92.08 Million USD | -1192.836% |
| Abeona Therapeutics Inc. | 17.93 Million USD | -6536.351% |
| Pliant Therapeutics, Inc. | 185.72 Million USD | -540.999% |
| Tonix Pharmaceuticals Holding Corp. | 121.4 Million USD | -880.582% |
| Histogen Inc. | 14.27 Million USD | -8241.473% |
| Aprea Therapeutics, Inc. | 16.04 Million USD | -7318.273% |
| Surrozen, Inc. | 18.55 Million USD | -6317.763% |
| Organovo Holdings, Inc. | 14.91 Million USD | -7881.864% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -23287.815% |
| Ovid Therapeutics Inc. | 59.67 Million USD | -1895.026% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -4541.849% |
| CASI Pharmaceuticals, Inc. | 47 Million USD | -2432.645% |
| Cadrenal Therapeutics, Inc. Common Stock | 7.63 Million USD | -15497.006% |
| Centessa Pharmaceuticals plc | 178.13 Million USD | -568.307% |
| Hepion Pharmaceuticals, Inc. | 48.44 Million USD | -2357.266% |
| Arcturus Therapeutics Holdings Inc. | 245 Million USD | -385.908% |
| BioRestorative Therapies, Inc. | 15.36 Million USD | -7647.303% |
| Apollomics, Inc. | 54.14 Million USD | -2098.919% |
| Amarin Corporation plc | 272.35 Million USD | -337.108% |
| Mesoblast Limited | 5.9 Million USD | -20071.044% |
| Turnstone Biologics Corp. | 78.33 Million USD | -1419.69% |
| Kymera Therapeutics, Inc. | 244.12 Million USD | -387.664% |
| Synaptogenix, Inc. | 8.31 Million USD | -14219.412% |
| Tiziana Life Sciences Ltd | 14.58 Million USD | -8061.902% |
| Aurinia Pharmaceuticals Inc. | 253.05 Million USD | -370.447% |
| BriaCell Therapeutics Corp. | 33.33 Million USD | -3471.834% |
| Monopar Therapeutics Inc. | 8.83 Million USD | -13380.504% |
| Exelixis, Inc. | 1.58 Billion USD | 24.974% |
| Better Therapeutics, Inc. | 38.26 Million USD | -3011.429% |
| Nurix Therapeutics, Inc. | 232.05 Million USD | -413.034% |
| Apellis Pharmaceuticals, Inc. | 855.2 Million USD | -39.206% |
| NLS Pharmaceutics AG | 11.8 Million USD | -9982.905% |
| Dermata Therapeutics, Inc. | 8.04 Million USD | -14703.642% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -3869.243% |
| Gritstone bio, Inc. | 148.37 Million USD | -702.361% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -1628.838% |
| TNF Pharmaceuticals, Inc. | 16.36 Million USD | -7176.767% |
| Avid Bioservices, Inc. | 25.99 Million USD | -4479.531% |
| Insmed Incorporated | 949.26 Million USD | -25.413% |
| Virpax Pharmaceuticals, Inc. | 15.68 Million USD | -7487.706% |
| MediWound Ltd. | 18.86 Million USD | -6209.598% |
| OmniAb, Inc. | 83.89 Million USD | -1319.03% |
| Alector, Inc. | 248.8 Million USD | -378.491% |
| Seres Therapeutics, Inc. | 234.3 Million USD | -408.09% |
| Checkpoint Therapeutics, Inc. | 52.25 Million USD | -2178.416% |
| Zai Lab Limited | 547.47 Million USD | -117.452% |
| Revance Therapeutics, Inc. | 398.65 Million USD | -198.629% |
| Aura Biosciences, Inc. | 84.99 Million USD | -1300.731% |
| Lyell Immunopharma, Inc. | 247.13 Million USD | -381.713% |
| Immunic, Inc. | 99.22 Million USD | -1099.818% |
| Tarsus Pharmaceuticals, Inc. | 159.01 Million USD | -648.682% |
| Veracyte, Inc. | 357.93 Million USD | -232.603% |
| InMed Pharmaceuticals Inc. | 9.01 Billion USD | 86.795% |
| FibroGen, Inc. | 398.11 Million USD | -199.034% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -8277.868% |
| Adial Pharmaceuticals, Inc. | 6.88 Million USD | -17183.742% |
| Sonnet BioTherapeutics Holdings, Inc. | 7.12 Million USD | -16606.985% |
| Jazz Pharmaceuticals plc | 3.25 Billion USD | 63.433% |
| Cyclacel Pharmaceuticals, Inc. | 25.87 Million USD | -4501.303% |
| Amylyx Pharmaceuticals, Inc. | 316.54 Million USD | -276.093% |
| TG Therapeutics, Inc. | 198.47 Million USD | -499.821% |
| Galecto, Inc. | 35.62 Million USD | -3241.553% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -2825.84% |
| Fortrea Holdings Inc. | 457.3 Million USD | -160.331% |
| KalVista Pharmaceuticals, Inc. | 54.27 Million USD | -2093.329% |
| Aptevo Therapeutics Inc. | 28.87 Million USD | -4022.498% |
| XBiotech Inc. | 37.51 Million USD | -3073.807% |
| Jasper Therapeutics, Inc. | 68.86 Million USD | -1628.838% |
| Lyra Therapeutics, Inc. | 20.64 Million USD | -5665.388% |
| Foghorn Therapeutics Inc. | 142.06 Million USD | -738.017% |
| Y-mAbs Therapeutics, Inc. | 99.07 Million USD | -1101.61% |
| Theravance Biopharma, Inc. | 110.71 Million USD | -975.269% |
| Ultragenyx Pharmaceutical Inc. | 958.24 Million USD | -24.237% |
| Metagenomi, Inc. Common Stock | 28.84 Million USD | -4027.214% |
| Vaxxinity, Inc. | 56.05 Million USD | -2023.95% |
| BioCryst Pharmaceuticals, Inc. | 430.64 Million USD | -176.448% |
| Gain Therapeutics, Inc. | 22.3 Million USD | -5236.553% |
| Cartesian Therapeutics, Inc. | 110.86 Million USD | -973.805% |
| NexImmune, Inc. | 28.16 Million USD | -4126.483% |
| Creative Medical Technology Holdings, Inc. | 5.53 Million USD | -21424.249% |
| Marker Therapeutics, Inc. | 17.89 Million USD | -6553.594% |
| Regeneron Pharmaceuticals, Inc. | 2.81 Billion USD | 57.713% |
| Chemomab Therapeutics Ltd. | 25.45 Million USD | -4576.126% |
| Scopus BioPharma Inc. | 11.71 Million USD | -10062.249% |
| RAPT Therapeutics, Inc. | 127.06 Million USD | -836.94% |
| Ainos, Inc. | 12.95 Million USD | -9091.122% |
| Pluri Inc. | 22.48 Million USD | -5195.796% |
| Prothena Corporation plc | 282.4 Million USD | -321.554% |
| Adaptimmune Therapeutics plc | 200.02 Million USD | -495.182% |
| Celularity Inc. | 215.05 Million USD | -453.569% |
| Rallybio Corporation | 78.93 Million USD | -1408.254% |
| Cue Biopharma, Inc. | 19.54 Million USD | -5991.981% |
| MeiraGTx Holdings plc | 151.07 Million USD | -688.0% |
| Omeros Corporation | 94.75 Million USD | -1156.446% |
| Humacyte, Inc. | 23.49 Million USD | -4966.583% |
| Immunocore Holdings plc | 308.04 Million USD | -286.474% |
| Cocrystal Pharma, Inc. | 3.39 Million USD | -35017.847% |
| Cidara Therapeutics, Inc. | 86.86 Million USD | -1270.512% |
| Blueprint Medicines Corporation | 722.86 Million USD | -64.692% |
| CalciMedica, Inc. | 21.81 Million USD | -5356.731% |
| Cabaletta Bio, Inc. | 74.66 Million USD | -1494.555% |
| Marinus Pharmaceuticals, Inc. | 160.54 Million USD | -641.557% |
| Scholar Rock Holding Corporation | 171.29 Million USD | -594.997% |
| Sana Biotechnology, Inc. | 294.94 Million USD | -303.64% |
| Pulmatrix, Inc. | 22.03 Million USD | -5302.01% |
| Elicio Therapeutics, Inc. | 34.57 Million USD | -3343.225% |
| Vigil Neuroscience, Inc. | 88.86 Million USD | -1239.652% |
| Intellia Therapeutics, Inc. | 551.56 Million USD | -115.839% |
| Adlai Nortye Ltd. American Depositary Shares | 72.55 Million USD | -1540.908% |
| Cytokinetics, Incorporated | 173.61 Million USD | -585.722% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -3358.831% |
| Nutriband Inc. | 5.73 Million USD | -20661.921% |
| Protara Therapeutics, Inc. | 43.61 Million USD | -2629.679% |
| Vor Biopharma Inc. | 126.03 Million USD | -844.567% |
| Roivant Sciences Ltd. | 1.18 Billion USD | -0.111% |
| Evogene Ltd. | 27.79 Million USD | -4183.897% |
| ProKidney Corp. | 151.52 Million USD | -685.691% |
| Applied Therapeutics, Inc. | 74.17 Million USD | -1504.981% |
| Hoth Therapeutics, Inc. | 7.69 Million USD | -15376.567% |
| BridgeBio Pharma, Inc. | 614.22 Million USD | -93.82% |
| CorMedix Inc. | 48.95 Million USD | -2331.676% |
| BioLineRx Ltd. | 50.8 Million USD | -2243.402% |
| Tango Therapeutics, Inc. | 150.7 Million USD | -689.977% |
| Galectin Therapeutics Inc. | 38.07 Million USD | -3026.957% |
| Atai Life Sciences N.V. | 125.78 Million USD | -846.452% |
| Renovaro Biosciences Inc. | 81.63 Million USD | -1358.238% |
| Aerovate Therapeutics, Inc. | 81.4 Million USD | -1362.363% |
| Zentalis Pharmaceuticals, Inc. | 252.55 Million USD | -371.386% |
| Sagimet Biosciences Inc. | 32.74 Million USD | -3536.21% |
| MediciNova, Inc. | 10.9 Million USD | -10821.707% |
| Praxis Precision Medicines, Inc. | 128.82 Million USD | -824.154% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -16299.078% |
| GeoVax Labs, Inc. | 6.02 Million USD | -19668.529% |
| Axsome Therapeutics, Inc. | 476.36 Million USD | -149.915% |
| Biomea Fusion, Inc. | 126.13 Million USD | -843.826% |
| PTC Therapeutics, Inc. | 1.31 Billion USD | 9.25% |
| Mereo BioPharma Group plc | 35.84 Million USD | -3221.508% |
| Cullinan Oncology, Inc. | 191.08 Million USD | -523.006% |
| Syndax Pharmaceuticals, Inc. | 229.95 Million USD | -417.71% |
| Absci Corporation | 73.66 Million USD | -1516.071% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -4216.203% |
| 4D Molecular Therapeutics, Inc. | 133.59 Million USD | -791.156% |
| Dyne Therapeutics, Inc. | 242.16 Million USD | -391.611% |
| Kiniksa Pharmaceuticals, Ltd. | 262.04 Million USD | -354.304% |
| Ventyx Biosciences, Inc. | 207.99 Million USD | -472.37% |
| Allakos Inc. | 196.05 Million USD | -507.222% |
| Imunon, Inc. | 20.31 Million USD | -5761.497% |
| Fulcrum Therapeutics, Inc. | 113.46 Million USD | -949.181% |
| Corcept Therapeutics Incorporated | 368.61 Million USD | -222.967% |
| BioAtla, Inc. | 129.68 Million USD | -817.976% |
| NLS Pharmaceutics AG | 11.8 Million USD | -9982.905% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -7414.328% |
| Allogene Therapeutics, Inc. | 84.91 Million USD | -1301.935% |
| Larimar Therapeutics, Inc. | 41.75 Million USD | -2750.939% |
| XOMA Corporation | 46.46 Million USD | -2462.243% |
| Kezar Life Sciences, Inc. | 111.17 Million USD | -970.868% |
| Cara Therapeutics, Inc. | 142.46 Million USD | -735.652% |
| aTyr Pharma, Inc. | 12.97 Million USD | -9072.471% |
| Aligos Therapeutics, Inc. | 103.65 Million USD | -1048.506% |
| Akero Therapeutics, Inc. | 172.87 Million USD | -588.665% |
| Viridian Therapeutics, Inc. | 254.76 Million USD | -367.293% |
| Eliem Therapeutics, Inc. | 37.4 Million USD | -3082.461% |
| EyeGate Pharmaceuticals, Inc. | 8.22 Million USD | -14374.431% |
| Akari Therapeutics, Plc | 16.8 Million USD | -6983.75% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -52253.153% |
| Halozyme Therapeutics, Inc. | 299.31 Million USD | -297.736% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -17592.715% |
| UroGen Pharma Ltd. | 138.88 Million USD | -757.162% |
| Sutro Biopharma, Inc. | 243 Million USD | -389.897% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -16265.043% |
| Orgenesis Inc. | 45.75 Million USD | -2501.777% |
| Entera Bio Ltd. | 8.86 Million USD | -13336.738% |
| GH Research PLC | 41.22 Million USD | -2788.009% |
| Lisata Therapeutics, Inc. | 25.7 Million USD | -4530.835% |
| Reneo Pharmaceuticals, Inc. | 83.05 Million USD | -1333.416% |
| Xencor, Inc. | 306.97 Million USD | -287.812% |
| 60 Degrees Pharmaceuticals, Inc. | 4.93 Million USD | -24030.322% |
| Replimune Group, Inc. | 234.77 Million USD | -407.083% |
| Coeptis Therapeutics Holdings, Inc. | 20.48 Million USD | -5710.159% |
| Vanda Pharmaceuticals Inc. | 191.79 Million USD | -520.709% |
| Lexaria Bioscience Corp. | 6.72 Million USD | -17592.715% |
| Portage Biotech Inc. | 18.19 Million USD | -6441.541% |
| Cardio Diagnostics Holdings, Inc. | 7.25 Million USD | -16299.078% |
| Olema Pharmaceuticals, Inc. | 104.96 Million USD | -1034.226% |
| OncoCyte Corporation | 25.63 Million USD | -4543.66% |
| Qualigen Therapeutics, Inc. | 6.09 Million USD | -19430.377% |
| Processa Pharmaceuticals, Inc. | 11.45 Million USD | -10290.928% |
| Purple Biotech Ltd. | -22.46 Million USD | 5398.861% |
| CollPlant Biotechnologies Ltd. | 16.48 Million USD | -7123.877% |
| scPharmaceuticals Inc. | 65.17 Million USD | -1726.529% |
| ProMIS Neurosciences, Inc. | 8.45 Million USD | -13984.138% |
| HilleVax, Inc. | 133.34 Million USD | -792.793% |
| NeuroSense Therapeutics Ltd. | 10.28 Million USD | -11475.061% |
| Tharimmune, Inc. | 9.45 Million USD | -12490.876% |
| Genprex, Inc. | 31.06 Million USD | -3732.818% |
| Neumora Therapeutics, Inc. Common Stock | 187.52 Million USD | -534.843% |
| Atossa Therapeutics, Inc. | 31.37 Million USD | -3694.165% |
| XTL Biopharmaceuticals Ltd. | 765 Thousand USD | -155520.261% |
| Virios Therapeutics, Inc. | 5.44 Million USD | -21756.301% |
| OKYO Pharma Limited | 8243.57 USD | -14441398.04% |
| Savara Inc. | 15.74 Million USD | -7461.099% |
| Curis, Inc. | 58.35 Million USD | -1940.091% |
| Daré Bioscience, Inc. | 33.6 Million USD | -3442.149% |
| Carmell Therapeutics Corporation | 5.09 Million USD | -23277.473% |
| Titan Pharmaceuticals, Inc. | 7.46 Million USD | -15856.239% |
| Achieve Life Sciences, Inc. | 27.02 Million USD | -4305.651% |
| BeiGene, Ltd. | 3.28 Billion USD | 63.777% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -5870.596% |
| Revolution Medicines, Inc. Warrant | 498.76 Million USD | -138.689% |
| Protagonist Therapeutics, Inc. | 153.65 Million USD | -674.8% |
| Erasca, Inc. | 141.52 Million USD | -741.191% |
| bluebird bio, Inc. | 240.23 Million USD | -395.561% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -26197.81% |
| BioMarin Pharmaceutical Inc. | 1.74 Billion USD | 31.827% |
| DBV Technologies S.A. | 92.16 Million USD | -1191.77% |
| Protagenic Therapeutics, Inc. | 4.52 Million USD | -26197.81% |
| Moderna, Inc. | 6.39 Billion USD | 81.381% |
| Vincerx Pharma, Inc. | 42.6 Million USD | -2693.999% |
| Fresh Tracks Therapeutics, Inc. | 14.36 Million USD | -8186.893% |
| Molecular Templates, Inc. | 63.09 Million USD | -1786.949% |
| Acrivon Therapeutics, Inc. Common Stock | 66.7 Million USD | -1684.823% |
| Travere Therapeutics, Inc. | 472 Million USD | -152.222% |
| Monte Rosa Therapeutics, Inc. | 143.31 Million USD | -730.707% |
| Spruce Biosciences, Inc. | 62.08 Million USD | -1817.617% |
| Celldex Therapeutics, Inc. | 43.41 Million USD | -2642.191% |
| Cogent Biosciences, Inc. | 208.13 Million USD | -471.996% |
| MacroGenics, Inc. | 217.21 Million USD | -448.072% |
| RenovoRx, Inc. | 11.39 Million USD | -10346.604% |
| Adicet Bio, Inc. | 152.03 Million USD | -683.025% |
| Prime Medicine, Inc. | 186.63 Million USD | -537.86% |
| Aditxt, Inc. | 25.95 Million USD | -4487.514% |
| Adagene Inc. | 41.83 Million USD | -2745.939% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -16185.623% |
| Quantum-Si incorporated | 111.65 Million USD | -966.188% |
| Maravai LifeSciences Holdings, Inc. | 171.85 Million USD | -592.752% |
| Acurx Pharmaceuticals, Inc. | 14.57 Million USD | -8066.511% |
| Voyager Therapeutics, Inc. | 35.82 Million USD | -3223.363% |
| SciSparc Ltd. | 9.01 Million USD | -13111.575% |
| Vericel Corporation | 142.04 Million USD | -738.141% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -13652.353% |
| Minerva Neurosciences, Inc. | 23.08 Million USD | -5056.204% |
| Generation Bio Co. | 144.46 Million USD | -724.06% |
| Astria Therapeutics, Inc. | 83.03 Million USD | -1333.813% |
| Black Diamond Therapeutics, Inc. | 86.46 Million USD | -1276.932% |
| Arcutis Biotherapeutics, Inc. | 295.72 Million USD | -302.575% |
| Invivyd, Inc. | 205.75 Million USD | -478.598% |
| Relay Therapeutics, Inc. | 72.15 Million USD | -1549.822% |
| Quoin Pharmaceuticals, Ltd. | 9.37 Million USD | -12593.869% |
| Spero Therapeutics, Inc. | 75.25 Million USD | -1481.969% |
| Artelo Biosciences, Inc. | 10.28 Million USD | -11472.81% |
| 2seventy bio, Inc. | 289.88 Million USD | -310.676% |
| ADMA Biologics, Inc. | 66.58 Million USD | -1687.906% |
| Clene Inc. | 41.07 Million USD | -2798.486% |
| Capricor Therapeutics, Inc. | 12.8 Million USD | -9195.016% |
| Boundless Bio, Inc. Common Stock | 54.79 Million USD | -2072.595% |
| GeoVax Labs, Inc. | 6.02 Million USD | -19668.529% |
| Recursion Pharmaceuticals, Inc. | 352.04 Million USD | -238.163% |
| Citius Pharmaceuticals, Inc. | 36.73 Million USD | -3141.028% |
| Contineum Therapeutics, Inc. Class A Common Stock | 33.72 Million USD | -3429.693% |
| Relmada Therapeutics, Inc. | 103.7 Million USD | -1047.996% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -3553.058% |
| ALX Oncology Holdings Inc. | 170.27 Million USD | -599.148% |
| Vir Biotechnology, Inc. | 767.72 Million USD | -55.069% |
| Evaxion Biotech A/S | 22.27 Million USD | -5245.734% |
| Ocular Therapeutix, Inc. | 135.54 Million USD | -778.309% |
| Verve Therapeutics, Inc. | 234.88 Million USD | -406.848% |
| Trevena, Inc. | 38.41 Million USD | -2999.198% |
| Surrozen, Inc. | 18.55 Million USD | -6317.763% |
| Tyra Biosciences, Inc. | 79.94 Million USD | -1389.143% |
| Cingulate Inc. | 22.75 Million USD | -5130.832% |
| Galmed Pharmaceuticals Ltd. | -7.49 Million USD | 15990.216% |
| Unity Biotechnology, Inc. | 44.66 Million USD | -2565.267% |
| Tenax Therapeutics, Inc. | 8.23 Million USD | -14358.386% |
| Terns Pharmaceuticals, Inc. | 102.55 Million USD | -1060.802% |
| ACADIA Pharmaceuticals Inc. | 754.08 Million USD | -57.873% |
| Connect Biopharma Holdings Limited | 62.07 Million USD | -1817.864% |
| Clearmind Medicine Inc. | 8.74 Million USD | -13519.121% |
| Kronos Bio, Inc. | 128.11 Million USD | -829.218% |
| Bolt Biotherapeutics, Inc. | 84.07 Million USD | -1316.042% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -40489.877% |
| Viking Therapeutics, Inc. | 100.82 Million USD | -1080.73% |
| Statera Biopharma, Inc. | 28.82 Million USD | -4029.433% |
| ImmunityBio, Inc. | 362.87 Million USD | -228.076% |
| Korro Bio, Inc. | 84.53 Million USD | -1308.303% |
| Kineta, Inc. | 21.15 Million USD | -5527.222% |
| BioVie Inc. | 31.95 Million USD | -3626.095% |
| Codexis, Inc. | 66.51 Million USD | -1689.734% |
| Celularity Inc. | 215.05 Million USD | -453.569% |
| Crinetics Pharmaceuticals, Inc. | 226.62 Million USD | -425.324% |
| Celcuity Inc. | 66.23 Million USD | -1697.507% |
| Virax Biolabs Group Limited | 6.54 Million USD | -18083.65% |
| Cibus, Inc. | 320.3 Million USD | -271.675% |
| Eledon Pharmaceuticals, Inc. | 43 Million USD | -2668.593% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -3417.595% |
| IN8bio, Inc. | 30.33 Million USD | -3824.234% |
| Kodiak Sciences Inc. | 277.32 Million USD | -329.284% |
| Annexon, Inc. | 143.72 Million USD | -728.326% |
| Adverum Biotechnologies, Inc. | 127.59 Million USD | -833.056% |
| Assembly Biosciences, Inc. | 22.9 Million USD | -5096.626% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | -185914.844% |
| Ionis Pharmaceuticals, Inc. | 779.58 Million USD | -52.708% |
| Eyenovia, Inc. | 25.4 Million USD | -4585.799% |
| Puma Biotechnology, Inc. | 140.31 Million USD | -748.445% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -21304.081% |
| Xilio Therapeutics, Inc. | 79.13 Million USD | -1404.423% |
| Arcellx, Inc. | 200.19 Million USD | -494.656% |
| Cardiff Oncology, Inc. | 45.9 Million USD | -2493.671% |
| Enanta Pharmaceuticals, Inc. | 216.41 Million USD | -450.108% |
| Regulus Therapeutics Inc. | 9.95 Million USD | -11856.362% |
| Moolec Science SA | 52.75 Million USD | -2156.837% |
| Acumen Pharmaceuticals, Inc. | 61.13 Million USD | -1847.226% |
| Geron Corporation | 70.44 Million USD | -1590.06% |
| LAVA Therapeutics N.V. | 46.54 Million USD | -2458.004% |
| Royalty Pharma plc | 862.4 Million USD | -38.044% |
| Atea Pharmaceuticals, Inc. | 94.07 Million USD | -1165.515% |
| Greenwich LifeSciences, Inc. | 9.32 Million USD | -12662.78% |
| TFF Pharmaceuticals, Inc. | 22.62 Million USD | -5161.035% |
| Mersana Therapeutics, Inc. | 207.81 Million USD | -472.871% |
| Humacyte, Inc. | 23.49 Million USD | -4966.583% |
| Structure Therapeutics Inc. | 102.77 Million USD | -1058.351% |
| 89bio, Inc. | 151.2 Million USD | -687.344% |
| PMV Pharmaceuticals, Inc. | 80.13 Million USD | -1385.667% |
| Avenue Therapeutics, Inc. | 14.54 Million USD | -8087.724% |
| Genelux Corporation | 24.33 Million USD | -4792.11% |
| Trevi Therapeutics, Inc. | 33.92 Million USD | -3409.404% |
| Lexicon Pharmaceuticals, Inc. | 172.86 Million USD | -588.669% |
| Notable Labs, Ltd. | 14.77 Million USD | -7960.223% |
| Liquidia Corporation | 87.98 Million USD | -1253.081% |
| Mustang Bio, Inc. | 48.5 Million USD | -2354.578% |
| Immunovant, Inc. | 282.7 Million USD | -321.103% |
| Quantum-Si incorporated | 111.65 Million USD | -966.188% |
| Arbutus Biopharma Corporation | 22.54 Million USD | -5180.762% |
| DiaMedica Therapeutics Inc. | 21.26 Million USD | -5497.851% |
| Vera Therapeutics, Inc. | 102.01 Million USD | -1067.015% |
| Acasti Pharma Inc. | 11.3 Million USD | -10434.422% |
| MiNK Therapeutics, Inc. | 22.92 Million USD | -5093.881% |
| Pasithea Therapeutics Corp. | 15.97 Million USD | -7350.204% |
| Xenon Pharmaceuticals Inc. | 46.54 Million USD | -2457.894% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | -104828.255% |
| NeuroBo Pharmaceuticals, Inc. | 15.88 Million USD | -7393.988% |
| Tempest Therapeutics, Inc. | 29.15 Million USD | -3983.05% |
| Soleno Therapeutics, Inc. | 41.38 Million USD | -2776.704% |
| PepGen Inc. | 84.76 Million USD | -1304.449% |
| Moleculin Biotech, Inc. | 29.63 Million USD | -3917.735% |
| United Therapeutics Corporation | 885.1 Million USD | -34.504% |
| Nuvectis Pharma, Inc. | 22.89 Million USD | -5099.349% |
| Solid Biosciences Inc. | 104.31 Million USD | -1041.25% |
| BriaCell Therapeutics Corp. | 32.72 Million USD | -3537.817% |
| Immuneering Corporation | 58.41 Million USD | -1938.069% |
| Lixte Biotechnology Holdings, Inc. | 5.09 Million USD | -23287.815% |
| Silo Pharma, Inc. | 3.92 Million USD | -30255.398% |
| Belite Bio, Inc | 31.66 Million USD | -3659.3% |
| XOMA Corporation | 46.46 Million USD | -2462.243% |
| ARS Pharmaceuticals, Inc. | 67.55 Million USD | -1662.391% |
| Bionomics Limited | 17.89 Billion USD | 93.346% |
| Apogee Therapeutics, Inc. | 93 Million USD | -1180.061% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 3436.589% |
| uniQure N.V. | 285.08 Million USD | -317.592% |
| Cassava Sciences, Inc. | 105.95 Million USD | -1023.564% |
| Estrella Immunopharma, Inc. | 7.31 Million USD | -16185.623% |
| Poseida Therapeutics, Inc. | 194.2 Million USD | -513.003% |
| Forte Biosciences, Inc. | 32.47 Million USD | -3565.656% |
| Anebulo Pharmaceuticals, Inc. | 8.3 Million USD | -14228.2% |
| Enlivex Therapeutics Ltd. | 29.39 Million USD | -3949.991% |
| Conduit Pharmaceuticals Inc. | 5.56 Million USD | -21304.081% |
| SeaStar Medical Holding Corporation | 14.21 Million USD | -8277.868% |
| FibroBiologics, Inc. Common Stock | 8.88 Million USD | -13292.901% |
| Altimmune, Inc. | 30.55 Million USD | -3796.109% |
| Amicus Therapeutics, Inc. | 427.65 Million USD | -178.38% |
| Alpha Tau Medical Ltd. | -35.68 Million USD | 3436.589% |
| Compugen Ltd. | 43.97 Million USD | -2607.455% |
| Peak Bio, Inc. | 1249.13 USD | -95305832.929% |
| Zevra Therapeutics, Inc. | 74.12 Million USD | -1506.172% |
| Benitec Biopharma Inc. | 22.38 Million USD | -5218.984% |
| Spyre Therapeutics, Inc. | 243.18 Million USD | -389.535% |
| NKGen Biotech, Inc. Common Stock | 28.54 Million USD | -4070.883% |
| Zura Bio Limited | 62.63 Million USD | -1800.595% |
| PolyPid Ltd. | 21.04 Million USD | -5556.902% |
| Aileron Therapeutics, Inc. | 16.27 Million USD | -7214.42% |
| NKGen Biotech, Inc. Warrants | 28.54 Million USD | -4070.883% |
| Instil Bio, Inc. | 85.78 Million USD | -1287.766% |
| argenx SE | 1.53 Billion USD | 22.369% |
| Immunome, Inc. | 122.82 Million USD | -869.301% |
| Compass Therapeutics, Inc. | 48.47 Million USD | -2355.996% |
| Verona Pharma plc | 67.15 Million USD | -1672.855% |
| enGene Holdings Inc. Warrants | 25.88 Million USD | -4499.169% |
| Shattuck Labs, Inc. | 93.61 Million USD | -1171.706% |
| CervoMed Inc. | 14.95 Million USD | -7859.042% |
| LENZ Therapeutics, Inc. | 70.7 Million USD | -1583.797% |
| Plus Therapeutics, Inc. | 8.54 Million USD | -13833.696% |
| Dianthus Therapeutics, Inc. | 51 Million USD | -2234.304% |
| Moolec Science SA | 52.75 Million USD | -2156.837% |
| Enveric Biosciences, Inc. | 16.44 Million USD | -7137.738% |
| Inovio Pharmaceuticals, Inc. | 132.55 Million USD | -798.113% |
| AnaptysBio, Inc. | 181.56 Million USD | -555.674% |
| Design Therapeutics, Inc. | 78.19 Million USD | -1422.567% |
| Leap Therapeutics, Inc. | 87.04 Million USD | -1267.74% |
| NeurAxis, Inc. | 8.82 Million USD | -13395.841% |
| Seelos Therapeutics, Inc. | 12.58 Million USD | -9359.634% |
| Lumos Pharma, Inc. | 38.66 Million USD | -2978.999% |
| Achilles Therapeutics plc | 75.25 Million USD | -1481.948% |
| enGene Holdings Inc. Common Stock | 25.88 Million USD | -4499.169% |
| 180 Life Sciences Corp. | 13.47 Million USD | -8733.203% |
| Opiant Pharmaceuticals, Inc. | 26.5 Million USD | -4392.02% |
| CERo Therapeutics Holdings, Inc. | 2.93 Million USD | -40489.877% |
| Nutriband Inc. | 5.73 Million USD | -20661.921% |
| ORIC Pharmaceuticals, Inc. | 110.78 Million USD | -974.648% |
| CG Oncology, Inc. Common stock | 55.65 Million USD | -2039.139% |
| Fractyl Health, Inc. Common Stock | 50.87 Million USD | -2239.855% |
| Rani Therapeutics Holdings, Inc. | 66.09 Million USD | -1701.079% |
| MoonLake Immunotherapeutics | 54.12 Million USD | -2099.606% |
| Palisade Bio, Inc. | 13.32 Million USD | -8837.65% |
| Tourmaline Bio, Inc. | 45.4 Million USD | -2521.716% |
| Beam Therapeutics Inc. | 554.19 Million USD | -114.816% |
| Neurogene Inc. | 55.58 Million USD | -2041.833% |
| Mirum Pharmaceuticals, Inc. | 248.48 Million USD | -379.094% |
| AEON Biopharma, Inc. | 48.42 Million USD | -2358.228% |
| CARGO Therapeutics, Inc. Common Stock | 96.71 Million USD | -1130.995% |
| Sesen Bio, Inc. | 78.38 Million USD | -1418.857% |
| Enliven Therapeutics, Inc. | 83.52 Million USD | -1325.248% |
| Kiora Pharmaceuticals, Inc. | 12.58 Million USD | -9358.21% |
| Iovance Biotherapeutics, Inc. | 450.99 Million USD | -163.972% |
| Taysha Gene Therapies, Inc. | 87.89 Million USD | -1254.528% |
| Athira Pharma, Inc. | 125.46 Million USD | -848.859% |
| Vaccinex, Inc. | 23.45 Million USD | -4975.656% |
| HCW Biologics Inc. | 21.02 Million USD | -5561.604% |
| XOMA Corporation | 46.46 Million USD | -2462.243% |
| Nektar Therapeutics | 190.9 Million USD | -523.613% |
| Arvinas, Inc. | 480 Million USD | -148.02% |
| Tevogen Bio Holdings Inc. | 2.27 Million USD | -52253.153% |
| Merus N.V. | 200.49 Million USD | -493.781% |
| Omega Therapeutics, Inc. | 103.35 Million USD | -1051.85% |
| Quince Therapeutics, Inc. | 34.62 Million USD | -3338.749% |
| Rezolute, Inc. | 70.38 Million USD | -1591.356% |
| Clene Inc. | 41.07 Million USD | -2798.486% |
| Indaptus Therapeutics, Inc. | 16.37 Million USD | -7168.656% |
| BeyondSpring Inc. | 24.86 Million USD | -4687.834% |
| Synlogic, Inc. | 58.53 Million USD | -1933.922% |
| Allarity Therapeutics, Inc. | 17.89 Million USD | -6553.784% |
| Phio Pharmaceuticals Corp. | 4.49 Million USD | -26402.56% |
| Peak Bio, Inc. | 1249.13 USD | -95305832.929% |
| Werewolf Therapeutics, Inc. | 60.44 Million USD | -1869.518% |
| Krystal Biotech, Inc. | 160.42 Million USD | -642.084% |
| Karyopharm Therapeutics Inc. | 270.63 Million USD | -339.896% |
| SpringWorks Therapeutics, Inc. | 348.03 Million USD | -242.059% |
| Lipella Pharmaceuticals Inc. | 2.15 Million USD | -55098.972% |
| MannKind Corporation | 125.59 Million USD | -847.869% |
| Ikena Oncology, Inc. | 84.57 Million USD | -1307.587% |
| Cyclerion Therapeutics, Inc. | 9.64 Million USD | -12240.572% |
| Gyre Therapeutics, Inc. | 89.6 Million USD | -1228.663% |
| Gossamer Bio, Inc. | 183.75 Million USD | -547.857% |
| CohBar, Inc. | 12.38 Million USD | -9509.836% |
| Cognition Therapeutics, Inc. | 50.72 Million USD | -2247.005% |
| NRx Pharmaceuticals, Inc. | 27.58 Million USD | -4216.203% |
| Legend Biotech Corporation | 583.14 Million USD | -104.151% |
| Mural Oncology plc | 192.07 Million USD | -519.82% |
| Biora Therapeutics, Inc. | 67.14 Million USD | -1672.968% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -7273.645% |
| Disc Medicine, Inc. | 91.12 Million USD | -1206.442% |
| Champions Oncology, Inc. | 28.11 Million USD | -4135.13% |
| REGENXBIO Inc. | 321.15 Million USD | -270.689% |
| Ensysce Biosciences, Inc. | 5.36 Million USD | -22105.615% |
| Anavex Life Sciences Corp. | 55.75 Million USD | -2035.187% |
| Cellectar Biosciences, Inc. | 38.96 Million USD | -2955.635% |
| Edgewise Therapeutics, Inc. | 114.35 Million USD | -941.034% |
| Vaxart, Inc. | 90.72 Million USD | -1212.187% |
| PharmaCyte Biotech, Inc. | 8.52 Million USD | -13872.933% |
| Aldeyra Therapeutics, Inc. | 42.79 Million USD | -2681.915% |
| Cellectis S.A. | 97.32 Million USD | -1123.279% |
| Longeveron Inc. | 21.25 Million USD | -5502.329% |
| Repare Therapeutics Inc. | 167.35 Million USD | -611.351% |
| Sarepta Therapeutics, Inc. | 1.36 Billion USD | 12.516% |
| Inozyme Pharma, Inc. | 75.64 Million USD | -1473.792% |
| Revolution Medicines, Inc. | 498.76 Million USD | -138.689% |
| Nymox Pharmaceutical Corporation | 6.65 Million USD | -17796.798% |
| Third Harmonic Bio, Inc. | 43.95 Million USD | -2608.502% |
| ArriVent BioPharma, Inc. Common Stock | 74.59 Million USD | -1496.052% |
| AN2 Therapeutics, Inc. | 69.63 Million USD | -1609.622% |
| Anixa Biosciences, Inc. | 11.06 Million USD | -10663.969% |
| Vertex Pharmaceuticals Incorporated | 4.77 Billion USD | 75.068% |
| Denali Therapeutics Inc. | 527.23 Million USD | -125.802% |
| Revelation Biosciences, Inc. | 8.65 Million USD | -13652.353% |
| Veru Inc. | 101.34 Million USD | -1074.659% |
| Corvus Pharmaceuticals, Inc. | 23.4 Million USD | -4986.064% |
| Cingulate Inc. | 22.75 Million USD | -5130.832% |
| Passage Bio, Inc. | 108.38 Million USD | -998.354% |
| Context Therapeutics Inc. | 25.07 Million USD | -4648.188% |
| Exicure, Inc. | 14.07 Million USD | -8357.623% |
| Day One Biopharmaceuticals, Inc. | 206.06 Million USD | -477.731% |
| Oramed Pharmaceuticals Inc. | 43.3 Million USD | -2649.348% |
| Scinai Immunotherapeutics Ltd. | 9.17 Million USD | -12872.185% |
| Rhythm Pharmaceuticals, Inc. | 252.48 Million USD | -371.515% |
| Nuvalent, Inc. | 149.49 Million USD | -696.36% |
| ABVC BioPharma, Inc. | 8.06 Million USD | -14657.772% |
| Carisma Therapeutics, Inc. | 103.65 Million USD | -1048.572% |
| Unicycive Therapeutics, Inc. | 21.44 Million USD | -5450.352% |
| OmniAb, Inc. | 83.89 Million USD | -1319.03% |
| Anew Medical, Inc. | 1.3 Million USD | -91417.334% |
| Fennec Pharmaceuticals Inc. | 32.76 Million USD | -3533.546% |
| Lipocine Inc. | 15.08 Million USD | -7794.456% |
| Lexeo Therapeutics, Inc. Common Stock | 68.51 Million USD | -1637.619% |
| Nautilus Biotechnology, Inc. | 76.15 Million USD | -1463.314% |
| SAB Biotherapeutics, Inc. | 40.31 Million USD | -2853.033% |
| G1 Therapeutics, Inc. | 114.84 Million USD | -936.628% |
| Bellerophon Therapeutics, Inc. | 22.38 Million USD | -5218.509% |
| Sage Therapeutics, Inc. | 664.14 Million USD | -79.252% |
| Ocugen, Inc. | 71.56 Million USD | -1563.469% |
| Mind Medicine (MindMed) Inc. | 93.86 Million USD | -1168.292% |
| Q32 Bio Inc. | 92.68 Million USD | -1184.522% |
| Brainstorm Cell Therapeutics Inc. | 21.17 Million USD | -5522.438% |
| Alumis Inc. Common Stock | 158.17 Million USD | -652.649% |
| Equillium, Inc. | 50.6 Million USD | -2252.478% |
| Kyverna Therapeutics, Inc. | 62.4 Million USD | -1807.661% |
| Coya Therapeutics, Inc. | 13.9 Million USD | -8461.291% |
| CNS Pharmaceuticals, Inc. | 18.86 Million USD | -6210.566% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -2435.612% |
| Evelo Biosciences, Inc. | 108.46 Million USD | -997.574% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -9506.401% |
| Dominari Holdings Inc. | 23.83 Million USD | -4894.735% |
| Edesa Biotech, Inc. | 9.22 Million USD | -12808.232% |
| vTv Therapeutics Inc. | 11.9 Million USD | -9898.278% |
| Bio-Techne Corporation | 563.03 Million USD | -111.441% |
| Agios Pharmaceuticals, Inc. | 408.8 Million USD | -191.213% |
| Harmony Biosciences Holdings, Inc. | 268.75 Million USD | -342.965% |
| Prelude Therapeutics Incorporated | 132.27 Million USD | -800.002% |
| Candel Therapeutics, Inc. | 14.41 Million USD | -8161.016% |
| iTeos Therapeutics, Inc. | 163.69 Million USD | -627.26% |
| Nkarta, Inc. | 131.65 Million USD | -804.288% |
| BioCardia, Inc. | 12.12 Million USD | -9721.756% |
| Iterum Therapeutics plc | 47.46 Million USD | -2407.995% |